Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical ...( ASHBURN Va. Sept. 26 /- Innocoll ...),Health

ASHBURN, Va., Sept. 26 /PRNewswire/ -- Innocoll, Inc., a privately-held specialty pharmaceutical company, announced the following status and progress updates regarding its clinical development programs and specialty pharmaceutical operations:

- Three Investigational New Drug (IND) Applications already approved

in 2007.

- GENTAMICIN SURGICAL IMPLANT to commence two US phase 3 multi-centered

clinical trials for the prevention of surgical site infection.

- CollaRx(R) GENTAMICIN TOPICAL to commence a series of phase 2 clinical

trials for the treatment and prevention of infected diabetic foot

ulcers.

- BUPIVACAINE SURGICAL IMPLANT to commence a series of phase 2 clinical

trials for the management of post-operative pain in a variety of soft

tissue and orthopedic surgery models.

- First patient dosing in at least five different clinical trials (three

in phase 2 and two in phase 3) expected before the end of 2007.

- IND submission planned for CollaRx(R) BUPIVACAINE TOPICAL, a new product

opportunity for the management of painful chronic and acute wounds.

- US Launch of CollaGUARD(TM), an advanced wound care product developed by

Innocoll and its first to be launched in the US, is planned for the

fourth quarter 2007.

- European sales and marketing infrastructure sold to EUSA Pharma in

August 2007.

Commenting on the update, Dr. Michael Myers, President and CEO of Innocoll Inc., said, "Our successes over the past few months have established a solid platform on which to build the future growth of the business. We are looking forward to the launch of our first product in the US with CollaGUARD and are poised to commence the clinical development of an exciting portfolio of late- stage pharmaceutical products. According to recent market research performed by L.E.K. Consulting, these three products between them have projected ann
'/>"/>